Lilly Makes Billions of Weight-Loss Pills
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...
16h
Investor Outlook: Eli Lilly delivers another strong quarter as demand for GLP-1 drugs accelerates
Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...
Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.
The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug.
On October 27, 2025, Eli Lilly announced that the U.S. FDA approved a new, once-monthly single-injection maintenance regimen ...
Eli Lilly and Co. LLY has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback